AR120870A1 - Polipéptidos, complejos de proteínas y el método para obtenerlos - Google Patents
Polipéptidos, complejos de proteínas y el método para obtenerlosInfo
- Publication number
- AR120870A1 AR120870A1 ARP200103608A ARP200103608A AR120870A1 AR 120870 A1 AR120870 A1 AR 120870A1 AR P200103608 A ARP200103608 A AR P200103608A AR P200103608 A ARP200103608 A AR P200103608A AR 120870 A1 AR120870 A1 AR 120870A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- protein complexes
- present disclosure
- polypeptide
- multivalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951701P | 2019-12-20 | 2019-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120870A1 true AR120870A1 (es) | 2022-03-23 |
Family
ID=76476896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103608A AR120870A1 (es) | 2019-12-20 | 2020-12-21 | Polipéptidos, complejos de proteínas y el método para obtenerlos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230242676A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4077374A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023507033A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115003693A (cg-RX-API-DMAC7.html) |
| AR (1) | AR120870A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3171363A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907375B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119832A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| EP4400512A4 (en) * | 2021-09-10 | 2025-07-23 | Soter Biopharma Pte Ltd | ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE |
| MX2024003779A (es) | 2021-09-29 | 2024-04-19 | Kisoji Biotechnology Inc | Agentes de union dirigidos a celulas tumorales que expresan trop2. |
| WO2023088295A1 (zh) * | 2021-11-17 | 2023-05-25 | 江苏先声药业有限公司 | 一种多特异性抗体及其药物用途 |
| EP4599066A1 (en) * | 2022-10-03 | 2025-08-13 | Kisoji Biotechnology Inc. | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof |
| CN120265659A (zh) * | 2022-10-25 | 2025-07-04 | 加拿大商木曾路生物科技公司 | 靶向表达cd36的肿瘤细胞的结合剂 |
| KR20250112917A (ko) | 2022-12-12 | 2025-07-24 | 라노바 메디신즈 리미티드 | Pd1 및 vegf를 표적으로 하는 이중특이적 항체 |
| EP4688866A1 (en) * | 2023-04-04 | 2026-02-11 | Kisoji Biotechnology Inc. | Binding agents targeting trop2-expressing tumor cells |
| EP4520768A1 (en) * | 2023-09-06 | 2025-03-12 | BioNTech SE | Vhh-ch3 fusion proteins |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| US9527927B2 (en) * | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2015048272A1 (en) * | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
| CN110981957B (zh) * | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| JP6966330B2 (ja) * | 2015-05-01 | 2021-11-17 | インヒブルクス,インコーポレイティド | Iii型分泌装置標的化分子 |
| WO2016192613A1 (zh) * | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| JP7328761B2 (ja) * | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | 多価多重特異性ox40結合融合タンパク質 |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| DK3529269T3 (da) * | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| JP7543134B2 (ja) * | 2017-10-03 | 2024-09-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | システイン操作された抗原結合分子 |
| CN111836832A (zh) * | 2018-01-08 | 2020-10-27 | 南京传奇生物科技有限公司 | 多特异性抗原结合蛋白及其使用方法 |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2020
- 2020-12-18 CA CA3171363A patent/CA3171363A1/en active Pending
- 2020-12-18 EP EP20902077.5A patent/EP4077374A4/en active Pending
- 2020-12-18 CN CN202080094676.5A patent/CN115003693A/zh active Pending
- 2020-12-18 US US17/786,708 patent/US20230242676A1/en active Pending
- 2020-12-18 WO PCT/CA2020/051753 patent/WO2021119832A1/en not_active Ceased
- 2020-12-18 JP JP2022538373A patent/JP2023507033A/ja active Pending
- 2020-12-21 TW TW109145364A patent/TWI907375B/zh active
- 2020-12-21 AR ARP200103608A patent/AR120870A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021119832A1 (en) | 2021-06-24 |
| US20230242676A1 (en) | 2023-08-03 |
| TWI907375B (zh) | 2025-12-11 |
| TW202136294A (zh) | 2021-10-01 |
| CN115003693A (zh) | 2022-09-02 |
| CA3171363A1 (en) | 2021-06-24 |
| EP4077374A4 (en) | 2023-12-27 |
| EP4077374A1 (en) | 2022-10-26 |
| JP2023507033A (ja) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
| BR112022012112A2 (pt) | Agonistas de il2 e métodos de uso dos mesmos | |
| CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
| MX2021014286A (es) | Proteinas multiespecificas. | |
| CO2018013104A2 (es) | Polipéptidos de fusión cd40l-fc y sus métodos de uso | |
| MX2017015467A (es) | Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll. | |
| BR112018068703A2 (pt) | inibidores substituídos de menin-mll e métodos de uso | |
| MX385750B (es) | Compuestos y métodos para la degradación mejorada de proteinas específicas. | |
| MX380658B (es) | Variantes de region fc con union mejorada de la proteina a. | |
| MX2022014695A (es) | Anticuerpos anti-gitr y sus usos. | |
| EA202091342A2 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| CL2020003083A1 (es) | Inhibidores de masp-2 y métodos de uso | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| BR112017006602A2 (pt) | método de conjugação de um polipeptídeo | |
| CL2022001130A1 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| CO2022000804A2 (es) | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso | |
| BR112019011053A2 (pt) | moduladores da atividade do complemento | |
| MX2023013228A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| MX2017012553A (es) | Compuestos espirociclicos. | |
| EP4036744C0 (en) | BLOCKCHAIN LAYOUT WITH RESTRICTED TRANSACTION | |
| EP3963927C0 (en) | CONFIGURATION OF CARRYING UNITS FOR PURPOSES RELATED TO NON-MOBILITY | |
| BR112019003712A2 (pt) | composições marcadoras, e métodos para produção e uso das mesmas |